From: Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients
Parameter | Premenopause (n = 19) | Postmenopause (n = 21) | |||||
---|---|---|---|---|---|---|---|
βa | p | Confidence Interval 95 % | βa | p | Confidence Interval 95 % | ||
BMD femoral neck (g/cm2)b | All | −0.023 | <0.001 | (−0.032, −0.013) | −0.015 | 0.021 | (−0.027, −0.002) |
Clinical stage I, IIA (n = 17)c | −0.030 | 0.004 | (−0.047, −0.013) | −0.018 | 0.037 | (−0.034, −0.001) | |
Clinical stage IIB, IIIA, IIIB (n = 23)c | −0.017 | 0.007 | (−0.029, −0.006) | −0.0123 | 0.198 | (−0.032, 0.008) | |
BMD L2-L4 (g/cm2)b | All | −0.063 | <0.001 | (−0.086, −0.039) | −0.035 | 0.001 | (−0.054, −0.016) |
Clinical stage I, IIA (n = 17)c | −0.059 | 0.006 | (−0.095, −0.023) | −0.043 | <0.001 | (−0.059, −0.026) | |
Clinical stage IIB, IIIA, IIIB (n = 23)c | −0.066 | 0.003 | (−0.102, −0.029) | −0.029 | 0.088 | (−0.062, 0.005) | |
BMC (kg)b | All | −0.027 | 0.29 | (−0.078, 0.025) | −0.036 | 0.140 | (−0.085, 0.013) |
Clinical stage I, IIA (n = 17)c | −0.019 | 0.66 | (−0.118, 0.079) | −0.005 | 0.895 | (−0.088, 0.078) | |
Clinical stage IIB, IIIA, IIIB (n = 23)c | −0.032 | 0.33 | (−0.103, 0.038) | −0.059 | 0.078 | (−0.126, 0.008) |